ArticleNature reviews. Materials2025
Delivering living medicines with biomaterials.
Article in Nature reviews. Materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Single-cell transcriptome-guided biomimetic magnetothermal hydrogel microspheres for multimodal eradication of residual glioblastoma.Bioactive materials · 2026Article
- RL-QN15 accelerates vaginal mucosal repair by regulating inflammatory, autophagic, and apoptotic responses.Biochemistry and biophysics reports · 2026Article
- Injectable and viscoelastic click alginate hydrogels for spatio-temporal T cell administration in vivo.Materials today. Bio · 2026Article
- Silk-Inspired Design and Manufacturing of Robust Plantymers.Nature communications · 2026Article
- Endogenous living adjuvants for cancer vaccination: Concepts, mechanisms, and design principles.Materials today. Bio · 2026Article
- Engineered Escherichia coli as a microbial cell factory for intracellular protein delivery: strains, vectors, mechanisms, and therapeutic applications.Microbial cell factories · 2026Review
- Biomaterials in personalized drug delivery: innovations, challenges, and future directions.PeerJ · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The engineering of therapeutic living cells through genetic programming is poised to transform medicine. Diverse living medicines, including mammalian cells, fungi, bacteria, and viruses, are under development. However, for these medicines to progress in the clinic, new strategies are needed to successfully deliver them into the body. Unlike conventional small molecule and protein-based biologics, living medicines present distinct challenges for delivery, including the need to maintain viability, control replication, manage metabolism, and mitigate immunogenicity. This Review focuses on delivery strategies for living medicines, identifying key challenges and efforts to overcome them. We survey clinically adopted biomaterial strategies for delivering conventional drugs and explore how these approaches can be tailored for living medicines. Finally, we discuss remaining challenges and future directions towards next-generation living medicine delivery.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.